News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Deals
GlaxoSmithKline and Pfizer Inc. Says Future IPO Possible For ViiV Healthcare
November 10, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
NEW YORK Nov 9 (Reuters) - An HIV company set up a year ago by GlaxoSmithKline Plc (GSK.L) and Pfizer Inc (PFE.N) could be spun off and floated in an initial public offering once its drug pipeline has matured a little further.
Twitter
LinkedIn
Facebook
Email
Print
IPO
Pfizer
GlaxoSmithKline
MORE ON THIS TOPIC
M&A
Novartis To ‘Bolster’ Neuromuscular Pipeline With $12B Avidity Acquisition
October 26, 2025
·
2 min read
·
Heather McKenzie
Immunology and inflammation
Biogen Grows Immunology Pipeline With Vanqua’s Anti-Inflammatory Molecule
October 24, 2025
·
2 min read
·
Dan Samorodnitsky
Deals
Lilly Dives Deeper Into Gene Therapy With up to $262M Adverum Buy
October 24, 2025
·
2 min read
·
Heather McKenzie
Mergers & acquisitions
Alkermes’ up to $2.1B Purchase of Avadel Sets Groundwork for ‘Strategic Evolution’
October 23, 2025
·
2 min read
·
Tristan Manalac
